Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DREAMseq in Advanced Melanoma
NCT02224781Phase 3Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Sep 2015
- Primary completion
- Sep 2023
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nivolumab, ipilimumab, dabrafenib + trametinib and trametinib in melanoma, sponsored by National Cancer Institute. Primary endpoint: 2-year Overall Survival. Started Sep 2015; status: active, not recruiting.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02224781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02224781.